The antipsychotics have an elegant role in treating the schizophrenic patients,. Along with the non-pharmacological treatment .The success rates with newly diagnosed patients were better when drugs are used to reduce the risk of developing chronic conditions. The aim of this study is to assess the efficacy of olanzapine and risperidone among patients with schizophrenia. An assessment was made in newly diagnosed patients with schizophrenia to study the effect of olanzapine and risperidone prescribed to them and their personality changes. The study was conducted for 100 patients over a period of 6 months. Patients were divided into two groups and treated with olanzapine and risperidone . There was a significant difference in both the therapy, with the mean differences in both the groups. Statistically significantly greater proportion of the olanzapine-treated than risperidone-treated patients maintained their response. Both the drugs prescribed significantly improved the health condition of schizpohrenic patients. In individual drug therapy olanzapine is considered as the drug that has more efficacies with respect to the mean values. Though the personality change of the patients shows significant improvement, it can be improved much more through patient awareness programs and patient education.
Cite this article:
Kingston R, Elizabeth Mathew, Shivakumar Swamy. Assessment of Effect of Olanzapine Vs Risperidone among Patients with Schizophrenia In Terms of Personality Changes. Research J. Pharm. and Tech. 3(1): Jan.-Mar. 2010; Page 224-226.
Lloyd G.G, Sharpe M. C, Medical
psychiatry, Davidson’s Principles and Practice of Medicine, 19th
edition, Churchill Livingstone, 2002; 245-247.
S. Norquist and Darrel A. Regier, The
Epidemiology of Psychiatric Disorders and the De Facto Mental Health Care System, Annual Review of
Medicine, 1996; 47: 473-479.
Victor.I. Reus Psychiatric
Disorders, In: Eugene Braunwald, Anthony. S.Fauci, Dennis L. Kaspar, Stephen.
L.Hauser, Dan.L.Longo, J.Larry Jameson, Editors. Harrison’s Principles of
Internal Medicine, 15th edition. New York: Mc Graw-Hill, 2001; 2542.
Mark H. Beers and Robert Berkow,
The Merck Manual of Diagnosis and therapy, 17th edition, Merck
research Laboratories (USA), 1999; 1564.
Adrienne Z. Ables, Otis L.
Baughman, Antidepressants: Update on New Agents and Indications, Am Fam
Physician, 2003; 67: 547-554
Dahl AA, Grov EK, Moum T, Fossa SD,
Anxiety Depression and Quality of Life in caregivers of patients with cancer in
late palliative phase, Annals of Oncology, 2005; 16: 1185-1191
Pathiyil Ravi Shankar, Samit Roy,
Patterns of Prescription And Drug use in a Psychiatry outpatient Department in
a teaching hospital in western Nepal, The Internet journal of Pharmacology,
Donoghue, Timothy R. Hylan,
Antidepressants use in the Clinical Practice Efficacy vs Effectiveness, 2001;
Dan J. Stein, Elisabeth Wreford
Anderson, Malcolm Lader, Escitalopram versus Paroxetine for social anxiety
disorder: Analysis of Efficacy for different symptom dimensions, European
Neuropsychopharmacology, 2006; 16: 33-38.
M. Gorman, Justine M. Kent, Jeremy D. Coplan,
Current and Emerging Therapeutics of Anxiety and Stress Disorders,
American College of Neuropsychopharmacology, 2002; 5: 967-980.
11. Brian C. Lund, Michael Flaum, Laura A. Adam, Paul J.
Perry, Psychiatric Prescribing Trends and Practices in Iowa’s Prisons,
Psychiatric services, 2002; 53: 1023-1024.
12. Jain-ping Chen, Charles Barron, Keh-Ming Lin, Henry
Chung, Prescribing medication for Asians with mental disorder, west J med, 176;
13. Helena S. Johnson, Heidi M. Inderbitzen-Nolan, Ann M.
Schapman, A comparison between socially anxious and depressive symptomatology
in youth: a focus on perceived family environment, Anxiety Disorders, 2005; 19:
14. Niclo Csacaleda, Jean-Philip Boulenger, Pharmacologic
Treatment Effective in both Generalized Anxiety Disorder and Major Depressive
Disorder: Clinical and Theoretical implications, Can J Psychiatry, 1998; 43: